Why It Matters

The Indian Pharmaceutical Association (IPA) is focusing its federal advocacy on positioning India as a strategic partner rather than a supply chain threat. This advocacy occurs as Congress implements PBM reforms and evaluates patent reform bills intended to increase generic competition.

While the Trump administration has introduced a domestic reshoring agenda for pharmaceutical manufacturing, it also established a February 2026 U.S.-India trade framework. This framework restores specific trade treatments for Indian pharmaceuticals, reflecting a policy approach that addresses both domestic manufacturing incentives and the continued role of international generic suppliers in the U.S. market.

By the Numbers

The Indian Pharmaceutical Association spent $900,000 in the fourth quarter of 2025 through MEDSERCUREAN LLC, bringing total expenditures to $1,005,000 across nine disclosures since registering its first federal lobbying activity in May 2024. The firm deployed one lobbyist, Kathleen Davidson Jaeger, former CEO of the Association for Accessible Medicines and a specialist in patent law and generic regulation. According to the specific issue codes listed in its Lobbying Disclosure Act (LDA) filings, The IPA maintains consistent focus across Health Issues (8 instances), Trade (8 instances), Defense (4 instances), and Homeland Security (4 instances).

The Agenda

The Indian Pharmaceutical Association is advocating for transparency requirements for Pharmacy Benefit Managers (PBMs) and Group Purchasing “to ensure fair market practices” and a “level playing field" for generic drug competition. Following the enactment of PBM reforms in February 2026, the association is focusing on regulations to close Hatch-Waxman Act loopholes that delay generic drug entry. Additionally, the association is lobbying for "U.S.-India supply chain resiliency partnerships” to position Indian manufacturing as a strategic alternative to Chinese supply chains.

Broader Context

Active congressional efforts that align with IPA’s objectives include the PBM Reform Act of 2025 (H.R. 4317), the Pharmacy Benefit Manager Transparency Act of 2025 (S.526), and the Preserve Access to Affordable Generics and Biosimilars Act (S.1096).

As of late 2025, nearly 35 percent of India’s total pharmaceutical exports went to the United States, supplying “40 percent of U.S. generics demand”. The domestic manufacturing infrastructure for these essential medicines remained limited, with only 12% of total Active Pharmaceutical Ingredients (API) volume made in the US, excluding IV fluids.

To address this gap, Executive Order 14293 “directs federal agencies to eliminate regulatory hurdles, accelerate permitting, and prioritize domestic facilities”. This effort is reinforced by the Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act, which offers pharmaceutical companies various tax incentives for domestic production of generic medicines, including materials and testing.

Between The Lines

The IPA faces competing forces as Congress pursues PBM reforms and generic drug protections while simultaneously advancing supply chain reshoring. Recent PBM reform legislation directly aligns with IPA objectives, and the Senate Judiciary Committee has advanced bipartisan bills targeting patent-delay tactics. However, Trump administration reshoring efforts, including executive orders streamlining U.S. drug manufacturing and the Strategic Active Pharmaceutical Ingredients Reserve, create significant headwinds.

The February 2026 U.S.-India trade framework provides a provisional tariff exclusion for Indian generics, but binds this status to the "successful conclusion" of a final Interim Agreement. This creates a regulatory period where Indian manufacturers may secure a "specialized status"—pending the outcome of a U.S. national security investigation into foreign drug dependency.

While the recent framework de-escalates immediate trade tensions, the PILLS Act continues to advance tax credits for U.S.-based manufacturing. For the IPA, the objective has transitioned from mitigating broad tariffs to maintaining the value of a "specialized status" amid domestic policies that incentivize U.S.-based ingredient sourcing.

Competitive Landscape

The association operates alongside strategic allies such as Viatris Inc. and the and the Association for Accessible Medicines, who coordinate on generic market access and patent reform. Additionally, the IPA finds common ground with tech-driven advocates like Blink Health Ltd., who promote market-based solutions to reduce generic pricing, providing a consumer-focused counterweight to high-cost brand-name drugs.

Conversely, the IPA faces structural opposition from PhRMA, which lobbies for extended patent protections that can delay generic entries. Beyond industry-level competition, the IPA must navigate a political coalition—led by lawmakers like Senator Rick Scott —that has linked drug quality concerns to the reshoring movement. This coalition’s focus on foreign-site oversight serves as a political justification for the domestic incentives and restrictive "Buy American" mandates that currently challenge Indian pharmaceutical dominance.

The Bottom Line

The Indian Pharmaceutical Association’s lobbying efforts are directed toward maintaining India’s role as a primary supplier of affordable medicine while navigating a U.S. policy environment that increasingly prioritizes supply chain self-sufficiency.

The association is currently managing a period where provisional trade relief at the executive level coincides with a legislative trend toward domestic pharmaceutical production. While the February 2026 U.S.-India trade framework establishes a tariff carveout for generic exports, the PILLS Act and related reshoring initiatives continue to incentivize a transition to U.S.-based supply chains.

The association’s long-term stability depends on whether the final terms of the bilateral trade agreement can reconcile India’s export volume with the U.S. government’s focus on manufacturing and national security.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article